Neuren is significant undervalued ...
Neuren Pharma ( NEU.AX)
Marketcap: only 48 million A$
Price: 0,34 A$
Awesome Pipeline :
Glypromate MCI in CABG US Phase 3 ongoing
NNZ-2566 Severe TBI Phase 2a (deal with US Army)
NNZ-2566 Mild/Mod TBI Phase 2
Motiva Apathy Phase 2b
Taylor Collison
http://preset.sphilo.com/neuren/images/NEU%200708%20-%20Hamilton.pdf
By the end 1Q CY08, we expect Neuren to be running four major
efficacy trials; namely three Phase 2 trials for NNZ-2566 in
mild/moderate and severe TBI and Motiva™ in post stroke abulia/
depression coupled with the current Phase 3 trial for Glypromate® in
CABG. All indications potentially provide Neuren with first to market,
billion dollar opportunities. With a current market cap of $40.2m, Neuren
remains a solid value proposition in the sector, where FDA INDs for mid
to late stage clinical trials continues to remain a vexing proposition. We
maintain our Speculative Buy recommendation and price target of $1.30,
though expect to make changes to our valuation model once the
acquisition has closed, which we expect during the current Q.
- Forums
- ASX - By Stock
- GAA
- cheapest biotech stock on the asx
GAA
genepharm australasia limited
cheapest biotech stock on the asx
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GAA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online